Read by QxMD icon Read

Vit d

shared collection
32 papers 25 to 100 followers
By Erica Yama Nephrologist
Suetonia C Palmer, Sharon Gardner, Marcello Tonelli, Dimitris Mavridis, David W Johnson, Jonathan C Craig, Richard French, Marinella Ruospo, Giovanni F M Strippoli
BACKGROUND: Guidelines preferentially recommend noncalcium phosphate binders in adults with chronic kidney disease (CKD). We compare and rank phosphate-binder strategies for CKD. STUDY DESIGN: Network meta-analysis. SETTING & POPULATION: Adults with CKD. SELECTION CRITERIA FOR STUDIES: Randomized trials with allocation to phosphate binders. INTERVENTIONS: Sevelamer, lanthanum, iron, calcium, colestilan, bixalomer, nicotinic acid, and magnesium...
November 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Patrick S Parfrey, Geoffrey A Block, Ricardo Correa-Rotter, Tilman B Drüeke, Jürgen Floege, Charles A Herzog, Gerard M London, Kenneth W Mahaffey, Sharon M Moe, David C Wheeler, Glenn M Chertow
The effect of the calcimimetic cinacalcet on cardiovascular disease in patients undergoing hemodialysis with secondary hyperparathyroidism was assessed in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events trial. This was the largest (in size) and longest (in duration) randomized controlled clinical trial undertaken in this population. During planning, execution, analysis, and reporting of the trial, many lessons were learned, including those related to the use of a composite cardiovascular primary endpoint, definition of endpoints (particularly heart failure and severe unremitting hyperparathyroidism), importance of age for optimal stratification at randomization, use of unadjusted and adjusted intention-to-treat analysis for the primary outcome, how to respond to a lower-than-predicted event rate during the trial, development of a prespecified analytic plan that accounted for nonadherence and for cointerventions that diminished the power of the trial to observe a treatment effect, determination of the credibility of a subgroup effect, use of adverse effects database to investigate rare diseases, collection of blood for biomarker measurement not designated before trial initiation, and interpretation of the benefits-to-harms ratio for individual patients...
March 7, 2016: Clinical Journal of the American Society of Nephrology: CJASN
Deirdre Hahn, Elisabeth M Hodson, Jonathan C Craig
BACKGROUND: Bone disease is common in children with chronic kidney disease (CKD) and when untreated may result in bone deformities, bone pain, fractures and reduced growth rates. This is an update of a review first published in 2010. OBJECTIVES: This review aimed to examine the benefits (improved growth rates, reduced risk of bone fractures and deformities, reduction in PTH levels) and harms (hypercalcaemia, blood vessel calcification, deterioration in kidney function) of interventions (including vitamin D preparations and phosphate binders) for the prevention and treatment of metabolic bone disease in children with CKD...
November 12, 2015: Cochrane Database of Systematic Reviews
Sandro Mazzaferro, Marzia Pasquali
Cholecalciferol, the precursor of Vitamin D3, is a very old, highly conserved, molecule. Its presence is evident in non-mineralized 750 million-year-old living species, such as plankton. The more active metabolites, a receptor and a D binding protein, appear later, along with the increasing complexity of animal species living in the sea. In the sea, however, the biological function of vitamin D is unlikely to be linked with mineral metabolism, and we can hypothesize a relationship with an immune response. It is in terrestrial animals exhibiting cellular bone that the complexity of vitamin D increases...
January 2016: Nephrology, Dialysis, Transplantation
Zhuangzhu Liu, Guobin Su, Xinfeng Guo, Yifan Wu, Xusheng Liu, Chuan Zou, Lei Zhang, Qianchun Yang, Yuan Xu, Weizhong Ma
BACKGROUND: Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic dysfunction of mineral and bone metabolism in people with CKD. Recent research shows that phosphate retention plays a significant role in the development of CKD-MBD. Compared with drug therapies, dietary interventions may be simple, inexpensive and feasible for phosphate retention. However, there is little evidence to support these interventions. OBJECTIVES: Our objective was to assess the benefits and harms of any dietary intervention for preventing and treating CKD-MBD...
September 16, 2015: Cochrane Database of Systematic Reviews
Edward A Ross, Jin Tian, Hanna Abboud, Richard Hippensteel, Joel Z Melnick, Rajendra S Pradhan, Laura A Williams, L Lee Hamm, Stuart M Sprague
BACKGROUND/AIMS: Secondary hyperparathyroidism is a common complication of chronic kidney disease, resulting from inactivation of vitamin D receptor signaling and phosphate retention. Selective activation of vitamin D receptors with intravenous paricalcitol significantly reduced parathyroid hormone (PTH) levels with no significant hypercalcemia or hyperphosphatemia in predialysis and hemodialysis (HD) patients. This study investigates the effects of oral paricalcitol to reduce PTH in patients receiving chronic HD and peritoneal dialysis (PD)...
2008: American Journal of Nephrology
Rosa Ramos, Miguel Pérez Fontán, Emilio Sánchez, Auxiliadora Bajo, Francesc Barbosa, Mercè Borràs, Teresa González
AIMS: Recently, oral form of paricalcitol has allowed extension of treatment to ambulatory patients on peritoneal dialysis but few data have been published about the benefits of paricalcitol in this subgroup. A multicenter, retrospective study was carried out to increase current knowledge on the effectiveness and safety of paricalcitol in 162 peritoneal dialyzed patients with secondary hyperparathyroidism. METHODS: Case histories of patients treated with paricalcitol for at least 6 months were reviewed to extract data on 12 biochemical parameters related to bone disease and health status...
May 2013: Clinical Nephrology
Ema J Jamaluddin, Abdul Halim Abdul Gafor, Loo Chee Yean, Rizna Cader, Rozita Mohd, Norella C T Kong, Shamsul Azhar Shah
BACKGROUND: Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease. Our primary objective was to evaluate the efficacy of oral paricalcitol versus oral calcitriol on serum intact parathyroid hormone (iPTH) and mineral bone parameters in continuous ambulatory peritoneal dialysis (CAPD) patients with SHPT. The secondary objective was to analyze highly sensitive C-reactive protein (hsCRP) and peritoneal membrane function in both groups. METHODS: This was a prospective randomized control trial...
June 2014: Clinical and Experimental Nephrology
Chien-Liang Chen, Nai-Ching Chen, Huei-Lung Liang, Chih-Yang Hsu, Kang-Ju Chou, Hua-Chang Fang, Po-Tsang Lee
CONTEXT: Secondary hyperparathyroidism (SHPT) may worsen with administration of denosumab in chronic renal failure patients with low bone mass. OBJECTIVE: This study aimed to evaluate the short-term effect of coadministration of calcitriol and denosumab on PTH secretion and parathyroid structure and the incidence of adverse effects in patients with SHPT and low bone mass. DESIGN AND SETTING: This was a 24-week, open-label study at Kaohsiung Veterans General Hospital in Kaohsiung, Taiwan...
July 2015: Journal of Clinical Endocrinology and Metabolism
Louise A Beveridge, Allan D Struthers, Faisel Khan, Rolf Jorde, Robert Scragg, Helen M Macdonald, Jessica A Alvarez, Rebecca S Boxer, Andrea Dalbeni, Adam D Gepner, Nicole M Isbel, Thomas Larsen, Jitender Nagpal, William G Petchey, Hans Stricker, Franziska Strobel, Vin Tangpricha, Laura Toxqui, M Pilar Vaquero, Louise Wamberg, Armin Zittermann, Miles D Witham
IMPORTANCE: Low levels of vitamin D are associated with elevated blood pressure (BP) and future cardiovascular events. Whether vitamin D supplementation reduces BP and which patient characteristics predict a response remain unclear. OBJECTIVE: To systematically review whether supplementation with vitamin D or its analogues reduce BP. DATA SOURCES: We searched MEDLINE, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, and http://www...
May 2015: JAMA Internal Medicine
Jordi Bover, Pieter Evenepoel, Pablo Ureña-Torres, Marc G Vervloet, Vincent Brandenburg, Sandro Mazzaferro, Adrian Covic, David Goldsmith, Ziad A Massy, Mario Cozzolino
It is increasingly acknowledged that mineral and bone disorders (MBDs) contribute to the excessively high cardiovascular (CV) disease morbidity and mortality observed in patients with chronic kidney disease (CKD). There is ongoing debate as to whether screening for CV calcification, one of the hallmarks of CKD-MBD, should be implemented in clinical practice in patients with CKD. Issues to be considered in this controversy relate to prevalence, severity, relevance, and last but not least, modifiability and reversibility of vascular and valvular calcifications in the setting of CKD...
March 2015: Nephrology, Dialysis, Transplantation
Carmine Zoccali, Gerard London
No abstract text is available yet for this article.
March 2015: Nephrology, Dialysis, Transplantation
Carmine Zoccali, Gerard London
In this narrative review, we discuss the dynamics and pathobiology of calcium accumulation in the arterial system and then appraise the validity of vascular calcification as a surrogate end point in cardiovascular (CV) diseases and in chronic kidney disease (CKD) in particular. Calcification follows inflammation in human atherosclerosis and therefore most likely represents a secondary phenomenon. This phenomenon is proportional to the severity of antecedent inflammation and is perhaps a healing process. As such, vascular calcification is a disease marker and a prognostic factor but not a relevant aetiological factor in arterial disease in CKD patients...
March 2015: Nephrology, Dialysis, Transplantation
Jordi Bover, Pieter Evenepoel, Pablo Ureña-Torres, Marc G Vervloet, Vincent Brandenburg, Sandro Mazzaferro, Adrian Covic, David Goldsmith, Ziad A Massy, Mario Cozzolino
No abstract text is available yet for this article.
March 2015: Nephrology, Dialysis, Transplantation
Christoph Wanner
No abstract text is available yet for this article.
March 2015: Nephrology, Dialysis, Transplantation
Charlotte A Keyzer, Maarten A de Jong, G Fenna van Breda, Marc G Vervloet, Gozewijn D Laverman, Marc Hemmelder, Wilbert M Janssen, Hiddo J Lambers Heerspink, Gerjan Navis, Martin H de Borst
UNLABELLED: Optimal albuminuria reduction is considered essential to halting chronic kidney disease (CKD) progression. Both vitamin D receptor activator (VDRA) treatment and dietary sodium restriction potentiate the efficacy of renin-angiotensin-aldosterone-system (RAAS) blockade to reduce albuminuria. The ViRTUE study addresses whether a VDRA in combination with dietary sodium restriction provides further albuminuria reduction in non-diabetic CKD patients on top of RAAS blockade. The ViRTUE study is an investigator-initiated, prospective, multi-centre, randomized, double-blind (paricalcitol versus placebo), placebo-controlled trial targeting stage 1-3 CKD patients with residual albuminuria of >300 mg/day due to non-diabetic glomerular disease, despite angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use...
July 2016: Nephrology, Dialysis, Transplantation
(no author information available yet)
No abstract text is available yet for this article.
January 20, 2015: Annals of Internal Medicine
Eric D Labonté, Christopher W Carreras, Michael R Leadbetter, Kenji Kozuka, Jill Kohler, Samantha Koo-McCoy, Limin He, Edward Dy, Deborah Black, Ziyang Zhong, Ingrid Langsetmo, Andrew G Spencer, Noah Bell, Desiree Deshpande, Marc Navre, Jason G Lewis, Jeffrey W Jacobs, Dominique Charmot
In CKD, phosphate retention arising from diminished GFR is a key early step in a pathologic cascade leading to hyperthyroidism, metabolic bone disease, vascular calcification, and cardiovascular mortality. Tenapanor, a minimally systemically available inhibitor of the intestinal sodium-hydrogen exchanger 3, is being evaluated in clinical trials for its potential to (1) lower gastrointestinal sodium absorption, (2) improve fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD, and (3) reduce interdialytic weight gain and intradialytic hypotension in ESRD...
May 2015: Journal of the American Society of Nephrology: JASN
Vin Tangpricha, Haimanot Wasse
No abstract text is available yet for this article.
November 2014: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Matias Trillini, Monica Cortinovis, Piero Ruggenenti, Jorge Reyes Loaeza, Karen Courville, Claudia Ferrer-Siles, Silvia Prandini, Flavio Gaspari, Antonio Cannata, Alessandro Villa, Annalisa Perna, Eliana Gotti, Maria Rosa Caruso, Davide Martinetti, Giuseppe Remuzzi, Norberto Perico
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 µg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism...
May 2015: Journal of the American Society of Nephrology: JASN
2014-09-08 15:58:09
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"